Combination VM-26 and adriamycin for metastatic transitional cell carcinoma.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013280:Stomatitis / Q000139:chemically induced; D013713:Teniposide / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; D013713:Teniposide; D011034:Podophyllotoxin